New exploration of the treatment of nontuberculous mycobacterium lung disease: Moxifloxacin may be a first-line drug for the treatment of NTM-PD [post]

Binbin Feng, Meiying Lin, Qinghu Yan, Lihua Qiu
2022 unpublished
Objective: By comparing the results of moxifloxacin sensitivity test and clinical efficacy in nontuberculous mycobacterium lung disease (NTM-PD) further confirm the necessity of moxifloxacin as a first-line drug for the treatment of nontuberculous mycobacterium(NTM).Method: Positive samples of sputum, bronchoscope brush or alveolar lavage fluid cultured in Bactec MGIT960 system were retrospectively selected from inpatients in Shandong Provincial Chest Hospital, China from January 2015 to
more » ... r 2020. The strains were identified by MPB64 colloidal gold method, gene chip and microbial mass spectrum identification system. The drug detection of NTM was performed by microplate method, Meanwhile, the efficacy of moxifloxacin in NTM-PD treatment regimen was compared.Results: 1. Among the 575 patients with positive sample culture, the bacteria species of 485 patients were identified. A total of 19 species of NTM were detected, and the majority of them were Mycobacterium intracellulare (68.87%, 334/485).2.The results of microplate assay of 219 NTM patients showed that all NTM strains were highly sensitive to moxifloxacin, amikacin and clarithromycin [100.00%(219/219), 96.80%(212/219), 94.52% (207/219), respectively]. 3. This study showed that the bacteriological cure rate of the NTM-PD treatment regimen containing moxifloxacin was 73.68% (42/57), significantly higher than that of the regimen without moxifloxacin (55.45%, 56/101), and the difference was statistically significant (P<0.05).Conclusion: In this study, all the strains of NTM patients were 100% sensitive to moxifloxacin, and the clinical bacteriological cure rate of moxifloxacin containing regimen was significantly improved. Therefore, moxifloxacin is recommended as the first-line drug for the treatment of NTM.
doi:10.21203/ fatcat:n6ehrus4p5e6blfygsm34iar5i